Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Nascent Biotech, Inc. (NBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3511-0.0186 (-5.04%)
At close: 02:10PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3697
Open0.3700
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3502 - 0.3870
52 Week Range0.0400 - 0.3870
Volume233,521
Avg. Volume361,349
Market Cap37.823M
Beta (5Y Monthly)-3.75
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent

    Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the United States Patent and Trademark Office (the "USPTO") has issued a Notice of Allowance for claims related to the Company's lead candidate Pritumumab.

  • ACCESSWIRE

    Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

    VERO BEACH, FL / ACCESSWIRE / June 7, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the completion of the Third cohort in dosing patients for its Phase I trial for Brain Cancer.

  • ACCESSWIRE

    Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors

    VERO BEACH, FL / ACCESSWIRE / May 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers, is pleased to announce that its CEO, Sean Carrick, was recently interviewed by Proactive Investors (ProactiveInvestors.

Advertisement
Advertisement